Pelthos Therapeutics Inc. (PTHS)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $29.24M
Last updated: Nov 17, 2026 at 11:04 AM ET
Pelthos Therapeutics Inc. (PTHS) Financials: Revenue, Profit and Cash Flow
Pelthos Therapeutics reported revenue of $16.80M for the fiscal year ended Dec 31, 2025. That year, net income was -$43.32M with a net margin of -257.9%, operating cash flow was -$22.59M and free cash flow was -$30.59M. The quarter ended Sep 30, 2026 had revenue of $15.39M and net income of -$7.89M.
Revenue and Margins
Over the 5 years to Dec 2025, revenue grew from $199.93K, a compound annual rate of 142.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $16.80M | N/A | 76.3% | -193.1% | -257.9% |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2020 | $199.93K | N/A | 100.0% | -677.2% | -330.4% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Revenue | $16.80M | $0 | $0 | $0 | $0 | $199.93K |
| Cost of revenue | $3.99M | $0 | $0 | $0 | N/A | N/A |
| Gross profit | $12.81M | $0 | $0 | $0 | N/A | $199.93K |
| Research and development | $1.23M | $1.18M | $2.58M | $391.73K | $209.05K | $138.59K |
| Operating income | -$32.43M | -$7.57M | -$6.86M | -$2.32M | -$839.00K | -$1.35M |
| Net income | -$43.32M | -$7.96M | -$7.38M | -$2.46M | -$595.39K | -$660.58K |
| EBITDA | N/A | -$6.88M | -$6.67M | -$2.18M | -$595.13K | -$658.91K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.39M | $15.60M | $10.91M | $9.39M | $7.41M | $0 | $0 | -$3.53K | $0 | $3.53K | $0 | N/A |
| Gross profit | $13.73M | $11.99M | $9.23M | $7.72M | $5.09M | $0 | $0 | -$3.53K | $0 | $3.53K | $0 | N/A |
| Operating income | -$9.69M | -$17.32M | -$13.09M | -$12.00M | -$15.36M | -$3.23M | -$1.83M | -$1.82M | -$2.05M | -$1.76M | -$1.93M | -$3.88M |
| Net income | -$7.89M | -$23.42M | -$25.07M | -$21.66M | -$16.24M | -$3.45M | -$1.97M | -$1.93M | -$1.70M | -$1.77M | -$2.56M | -$4.04M |
Balance Sheet
As of Dec 2025, total debt of $32.08M exceeded cash and equivalents by $14.10M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Total assets | $130.40M | $1.37M | $96.39K | $55.07K | $0 | N/A |
| Current assets | $53.41M | $1.37M | $96.39K | $55.07K | $0 | N/A |
| Cash and equivalents | $17.97M | $513.00K | $96.39K | $55.07K | $0 | N/A |
| Total liabilities | $91.52M | $4.08M | $6.54M | $3.76M | $3.68M | N/A |
| Short-term debt | $635.00K | $2.19M | $750.08K | $104.80K | N/A | N/A |
| Long-term debt | $31.44M | $0 | N/A | N/A | N/A | N/A |
| Shareholder equity | $38.88M | -$2.71M | -$6.44M | -$3.71M | -$3.68M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $128.82M | $137.36M | $145.38M | $130.40M | $126.43M | $822.85K | $911.18K | $1.37M | $2.14M | $2.60M | $4.03M | $96.39K |
| Total liabilities | $135.00M | $138.86M | $126.11M | $91.52M | $68.18M | $7.32M | $5.11M | $4.08M | $3.57M | $2.79M | $2.90M | $6.54M |
| Cash and equivalents | $17.69M | $24.19M | $31.98M | $18.02M | $14.20M | $59.17K | $131.32K | $513.44K | $1.25M | $2.41M | $3.77M | $96.39K |
| Shareholder equity | -$6.19M | -$1.50M | $19.27M | $38.88M | $58.25M | -$6.49M | -$4.20M | -$2.71M | -$1.43M | -$182.52K | $1.13M | -$6.44M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$22.59M | -$5.79M | -$981.03K | -$1.57M | -$1.59M |
| Capital expenditures | $8.00M | $0 | $0 | $0 | $0 |
| Free cash flow | -$30.59M | -$5.79M | -$981.03K | -$1.57M | -$1.59M |
| Share repurchases | $0 | $75.00K | $0 | N/A | N/A |
| Investing cash flow | -$5.24M | $0 | $0 | $0 | N/A |
| Financing cash flow | $45.34M | $6.21M | $1.02M | $1.62M | $1.59M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.16M | -$7.66M | -$13.13M | -$6.25M | -$15.26M | -$447.00K | -$632.00K | -$670.00K | -$177.69K | -$2.95M | -$1.99M | -$356.81K |
| Capital expenditures | $60.00K | $2.00K | $194.00K | $99.00K | $0 | $5 | $0 | $0 | $0 | $0 | $0 | $3 |
| Free cash flow | -$5.22M | -$7.67M | -$13.32M | -$6.35M | -$15.26M | -$447.00K | -$632.00K | -$670.00K | -$177.69K | -$2.95M | -$1.99M | -$356.81K |
Frequently Asked Questions About PTHS
What is Pelthos Therapeutics' annual revenue?
Pelthos Therapeutics reported revenue of $16.80M for the fiscal year ended Dec 31, 2025.
Is Pelthos Therapeutics profitable?
No. Pelthos Therapeutics reported net income of -$43.32M for the fiscal year ended Dec 31, 2025, with a net margin of -257.9%.
How much free cash flow does PTHS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$22.59M minus capital expenditures of $8.00M produced free cash flow of -$30.59M.
How much debt does Pelthos Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $31.44M, short-term debt of $635.00K and cash and equivalents of $17.97M.
What is PTHS's profit margin?
For the fiscal year ended Dec 31, 2025, Pelthos Therapeutics reported gross margin of 76.3%, operating margin of -193.1% and net margin of -257.9%.
PTHS pages: Overview, Earnings, Forecast, Financials, Competitors